Talarico Giovanna, Orecchioni Stefania, Falvo Paolo, Bertolini Francesco
Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, 20141 Milan, Italy.
Cancers (Basel). 2025 Jul 4;17(13):2251. doi: 10.3390/cancers17132251.
The family of myeloid-derived suppressor cells (MDSCs) includes a heterogeneous group of partially immature cells belonging to the myeloid lineage with potent immunosuppressive functions. They might be increased in the peripheral blood of cancer patients and in the microenvironment of cancer lesions, where they act in suppressing adaptive and innate immune cells, promoting tumor progression, and facilitating resistance to therapy. Several-albeit still limited-studies have shown higher levels of MDSCs in elderly cancer patients, correlating with poorer outcomes and a reduced response to immunotherapies. Thus, MDSCs may serve as biomarkers for prognosis or therapy response in this population, and MDSC-targeting therapies aimed at reducing their number or function may enhance the effectiveness of immunotherapies in older adults. Additionally, a better understanding of MDSCs may help to overcome some age-related barriers in cancer treatments.
髓源性抑制细胞（MDSC）家族包括一群异质性的部分未成熟细胞，它们属于具有强大免疫抑制功能的髓系谱系。在癌症患者的外周血和癌症病灶的微环境中，它们的数量可能会增加，在这些地方它们发挥作用抑制适应性免疫细胞和固有免疫细胞，促进肿瘤进展，并促进对治疗的抵抗。一些研究（尽管仍然有限）表明老年癌症患者体内的MDSC水平较高，这与较差的预后和对免疫疗法的反应降低相关。因此，MDSC可能作为该人群预后或治疗反应的生物标志物，旨在减少其数量或功能的靶向MDSC疗法可能会提高免疫疗法在老年人中的有效性。此外，更好地了解MDSC可能有助于克服癌症治疗中一些与年龄相关的障碍。
